Vanguard Group’s BioSpecifics Technologies Corp. BSTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-311,761
| Closed | -$16.5M | – | 4239 |
|
|
2020
Q3 | $16.5M | Sell |
311,761
-331
| -0.1% | -$20.4K | ﹤0.01% | 2549 |
|
|
2020
Q2 | $19.1M | Buy |
312,092
+25,532
| +9% | +$1.48M | ﹤0.01% | 2451 |
|
|
2020
Q1 | $16.2M | Buy |
286,560
+1,397
| +0.5% | +$79.6K | ﹤0.01% | 2384 |
|
|
2019
Q4 | $16.2M | Sell |
285,163
-1,081
| -0.4% | -$57.3K | ﹤0.01% | 2629 |
|
|
2019
Q3 | $15.3M | Buy |
286,244
+9,011
| +3% | +$525K | ﹤0.01% | 2600 |
|
|
2019
Q2 | $16.6M | Buy |
277,233
+1,320
| +0.5% | +$83.1K | ﹤0.01% | 2606 |
|
|
2019
Q1 | $17.2M | Buy |
275,913
+6,014
| +2% | +$398K | ﹤0.01% | 2574 |
|
|
2018
Q4 | $16.4M | Buy |
269,899
+6,799
| +3% | +$406K | ﹤0.01% | 2529 |
|
|
2018
Q3 | $15.4M | Buy |
263,100
+3,433
| +1% | +$175K | ﹤0.01% | 2705 |
|
|
2018
Q2 | $11.6M | Buy |
259,667
+7,897
| +3% | +$340K | ﹤0.01% | 2826 |
|
|
2018
Q1 | $11.2M | Buy |
251,770
+16,975
| +7% | +$713K | ﹤0.01% | 2785 |
|
|
2017
Q4 | $10.2M | Buy |
234,795
+14,933
| +7% | +$671K | ﹤0.01% | 2809 |
|
|
2017
Q3 | $10.2M | Buy |
219,862
+19,408
| +10% | +$929K | ﹤0.01% | 2795 |
|
|
2017
Q2 | $9.92M | Buy |
200,454
+3,030
| +2% | +$159K | ﹤0.01% | 2773 |
|
|
2017
Q1 | $10.8M | Buy |
197,424
+1,879
| +1% | +$99.5K | ﹤0.01% | 2727 |
|
|
2016
Q4 | $10.9M | Sell |
195,545
-4,362
| -2% | -$210K | ﹤0.01% | 2710 |
|
|
2016
Q3 | $9.13M | Buy |
199,907
+2,130
| +1% | +$85.5K | ﹤0.01% | 2734 |
|
|
2016
Q2 | $7.9M | Buy |
197,777
+3,638
| +2% | +$133K | ﹤0.01% | 2757 |
|
|
2016
Q1 | $6.76M | Buy |
194,139
+10,168
| +6% | +$373K | ﹤0.01% | 2808 |
|
|
2015
Q4 | $7.91M | Buy |
183,971
+9,036
| +5% | +$453K | ﹤0.01% | 2765 |
|
|
2015
Q3 | $7.62M | Buy |
174,935
+30,651
| +21% | +$1.65M | ﹤0.01% | 2750 |
|
|
2015
Q2 | $7.45M | Buy |
144,284
+7,688
| +6% | +$328K | ﹤0.01% | 2818 |
|
|
2015
Q1 | $5.35M | Buy |
136,596
+7,884
| +6% | +$309K | ﹤0.01% | 2966 |
|
|
2014
Q4 | $4.97M | Buy |
128,712
+2,540
| +2% | +$96.9K | ﹤0.01% | 2905 |
|
|
2014
Q3 | $4.45M | Buy |
126,172
+3,954
| +3% | +$116K | ﹤0.01% | 2896 |
|
|
2014
Q2 | $3.29M | Buy |
122,218
+6,527
| +6% | +$170K | ﹤0.01% | 3039 |
|
|
2014
Q1 | $3M | Buy |
115,691
+6,082
| +6% | +$146K | ﹤0.01% | 3049 |
|
|
2013
Q4 | $2.38M | Buy |
109,609
+3,598
| +3% | +$73.7K | ﹤0.01% | 3122 |
|
|
2013
Q3 | $2.06M | Buy |
106,011
+624
| +0.6% | +$11.1K | ﹤0.01% | 3119 |
|
|
2013
Q2 | $1.64M | Buy |
+105,387
| New | +$1.7M | ﹤0.01% | 3137 |
|
Other funds holding BSTC
Vanguard Group's BSTC Position: Q4 2020 in Review
Vanguard Group sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 311,761 shares — an estimated $16.5M sold.
Vanguard Group first reported a position in BSTC in Q2 2013 and held it in 30 quarters. The position peaked at $19.1M in Q2 2020. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.
- Vanguard Group reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
- Vanguard Group sold 311,761 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $16.5M.
- Vanguard Group first reported a position in BioSpecifics Technologies Corp. in Q2 2013 and held it in 30 quarters.
- Vanguard Group's BioSpecifics Technologies Corp. position peaked at $19.1M in Q2 2020.
- 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.
Based on Vanguard Group's 13F filing for Q4 2020, filed 12 Feb 2021.